ALLWORTH DIAGNOSTICS LIMITED

Allworth Diagnostics is an early‑stage health‑technology company dedicated to empowering patients with inherited metabolic disorders (IMDs) through real‑time, at‑home monitoring of blood amino‑acid levels. By harnessing proprietary recombinant‑enzyme technology, advanced optical sensors and cloud‑based data algorithms, the firm delivers a rapid, single‑drop blood test that delivers precise results within two minutes.

The company’s flagship offering is a complete monitoring and data‑management system for the three most prevalent IMDs – phenylketonuria (PKU), galactosaemia and maple‑syrup urine disease (MSUD). Users obtain a finger‑stick sample, receive an instant amino‑acid reading via a smartphone‑linked app, and can view trends on a personalised portal that can be shared securely with healthcare providers. This approach replaces the traditional dried‑blood‑spot mailing process, eliminating delays of up to ten days and reducing sources of error.

Allworth Diagnostics’ expertise lies in developing enzymatic assays for notoriously difficult targets, providing the IMD community with a convenient, reliable tool for lifelong dietary and therapeutic management.